Mr. Harel has more than 30 years’ experience in sales, marketing, operation and business development in the global pharmaceutical industry. He demonstrated ability to establish strategic directions, to operate teams in international environments (Europe, Asia, U.S., Latin America, and Middle East) and to accomplish challenging business objectives. Mr. Harel is the founder and president of “The Harel Group”, a business development advisory firm supporting international transactions in the global pharmaceutical industry. Prior to founding “The Harel Group”, Mr. Harel spent more than 27 years at Merck & Co., Inc. in leadership roles in sales, marketing and business development. Most recently, as Executive Director and Head of Corporate Business Development, Mr. Harel led the negotiation and execution of key enterprise transactions, including joint ventures, divestitures, commercial collaborations, licensing and distribution agreements. Mr. Harel holds a Bachelor of Science degree in Economics, from Haifa University, and an MBA in marketing, from Tel Aviv University, Israel.
Mr. Hurvitz established CH-health, a private venture capital firm, and is serving as its CEO since May 2011. He is the chairman of Galmed Pharmaceuticals board of directors since 2011, board member in UroGen Pharma ltd. and a member of the presidency board of the Manufacturers Association of Israel, chairing its pharmaceutical branch. Mr. Hurvitz was a member of the board of directors in Teva from 2010 to July 2014 and held various top positions therein since 1992, including president of Teva International Group, president and CEO of Teva Pharmaceuticals Europe as well as VP of Israeli Pharmaceutical Sales. Mr. Hurvitz holds a Bachelor of Arts degree in Political Science and Economics from Tel Aviv University awarded in 1985.
Mr. Weisberg is leading PolyPid since 2010 and has 20 years of experience as an entrepreneur and CEO of start-up companies with two financial exits. Prior to PolyPid, Mr. Weisberg managed start-up companies in the Life Science sphere, from incubator stage to clinical trials, including leading the financing rounds for these companies.
Ms. Tsour Segal, business woman and entrepreneur, has over 20 years of experience in venture capital, seed stage investing, portfolio management, public companies and capital markets. Anat brings expertise in corporate finance and in various business and managerial areas, with strong focus on high-tech and med-tech sectors. From 2003 – 2016 Ms. Segal Founded and served as CEO of Xenia Venture Capital, a publicly traded investment company (TASE) and a technological incubator based in Israel. Since its inception, Xenia has executed more than 30 seed stage investments in technology and med tech sectors, established companies that have reached cumulative value of over $250m, raised over $150m from leading investors worldwide, and attained successful exits. Prior to founding Xenia, Anat led her independent consulting and investment banking practice, having advised to over 20 companies on business planning, corporate development, M&A’s and fund raising of private and public capital (NASDAQ, Tel-Aviv and European stock exchanges). Prior to that Anat was Managing Director & Head of Corporate Finance of Tamir Fishman, held senior Investment Banking positions with Robertson Stephens/Evergreen and Poalim Capital Markets and served as credit officer with Bank Hapoalim International Division. Ms. Tsour Segal holds a BA in Economics and Management, MBA and L.L.B. from the Tel Aviv University. Anat serves as a mentor in the entrepreneurship program in the graduate business school and in the design school of Colman College of Management. Anat also volunteers as a mentor in Tech for Good Rally, a social accelerator, as well as in other organizations that promote high tech entrepreneurship with emphasis on empowerment of women entrepreneurs.
Prof. Barenholz is a recognized expert in the field of drug delivery. Prof. Barenholz is the co-inventor of DoxilTM, a liposomal formulation of doxorubicin for cancer treatment marketed in the US by Johnson & Johnson and in Europe by Schering Plough (as Caelyx). Prof. Barenholz serves as head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry of the Hadassah Medical School at the Hebrew University of Jerusalem.
Dr. Emanuel has vast experience in biotechnology projects, including development of drug delivery systems and immunology. His extensive expertise includes immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery, and medical devices. Dr. Emanuel has a number of approved patents in the field of drug delivery and diagnostics. Dr. Emanuel is a co-founder of PolyPid and served as its CEO during the company’s first three years. He received his Ph.D. degree from the Faculty of Medicine at the Hebrew University of Jerusalem.
Mr. Kyiet has 15 years’ experience holding a senior operations and business planning position in Biosense Webster (a Johnson & Johnson company), several business development and strategic alliance positions with Lumenis and also an M&A and high-tech partner in a major Tel Aviv law firm and an in-house counsel to a publicly-traded company in Israel and on NASDAQ. He holds an LL.B. in law and an MBA, both from Haifa university.
With 17 years diverse industry experience, Dr. Frydman is currently Managing Director – Healthcare for Aurum Ventures MKI. Prior to his current position, he served as the Chief Business Officer of FutuRx, the drug development incubator established by J&J, Orbimed and Takeda. Prior to that, Eli served for 10 years as the COO of Aposense Ltd., a drug development and molecular imaging company (TASE: APOS), with responsibilities for business development, operations and finance. Before joining Aposense, he served as a Senior Business Development manager at GE Healthcare Europe (based in France), doing healthcare M&A across Europe. Eli holds an MBA from the Ecole des Ponts, Paris, and a PhD in Chemistry (nanotechnology) from the Weizmann Institute of Science.